Doug Boothe, Chief Executive Officer, Actavis Inc.
At Actavis, the products may be “generic,” but the way the company goes about developing, manufacturing, and marketing them is anything but.
In 1999, Actavis was in a single country, its home of Iceland, with fewer than 150 employees. In a matter of just a decade, with aggressive product development and the acquisition and successful integration of more than 25 companies across the globe, Actavis is now among the top 5 leading developers of generic pharmaceuticals in the world. All in all, the company has approximately 850 products on the market globally, with nearly 330 more in active development.
Actavis has one of the broadest product portfolios and strongest pipelines in the business, with products that cover the full gamut of dosage forms, including tablets, capsules, injectables, suppositories, powders, oral liquids, and semisolids. Diverse? Yes. But there’s one common element to them all: helping make pharmaceuticals more affordable for consumers.
A Goal Accomplished Through a Winning Strategy
Growth of more than 2600% in 10 years doesn’t come easy. But from its beginnings, Actavis has been well managed and aggressive. Actavis focuses on its customers and on providing high-quality, lower-cost products—with a strong pipeline of new products and a team that is committed to bringing those products to market.
The company of more than 10,000 works tirelessly to bring a wide range of high-quality generics to market and it keeps costs under control through continuous process improvement, resource optimization, and ongoing, careful analysis. It’s a formula that has helped propel Actavis to a leading position in markets across the world.
A Vision for the Future
After this intense period of growth, the company now has a solid foundation on which to build. Actavis is investing strongly in and growing its research and development capability. It is expanding its growing portfolio and dosage forms and enhancing its quality systems and production processes in its plants. And it anticipates launching numerous ANDAs this year, with many more to come.
For Actavis, it’s been a fascinating, fast-paced journey from a small Icelandic company to an international organization, but it’s one that was founded on the right idea: offering high-quality, affordable alternatives to brand name drugs.
A Quick Look at Actavis
• A leading developer and manufacturer of high-quality generics.
• Actavis has the world’s only pharmaceutical manufacturing facility completely powered by geothermal energy.
• More than 10,500 employees in 40 countries (including more than 1100 in the United States).
• Approximately 850 products on the market and 330 more on the way.
• Twenty-four billion tablet and capsule capacity.
• The name Actavis comes from 2 Latin words: acta, meaning action; and vis, meaning strength. PT
For more information, visit www.actavis.us.
Actavis proudly launched Oxymorphone Hydrochloride ExtendedRelease Tablets, CII, in 7.5-mg and 15-mg strengths. It is AB rated to Opana® * ER (oxymorphone hydrochloride) Extended-Release tablets. For Full Prescribing Information and other Important Safety Information, please visit www.actavis.us/oxymorphone.
At Actavis, we are working to meet the demand for high quality lower-cost alternatives to brand name pharmaceuticals.
*Opana® is a registered trademark of a party other than Actavis.
In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine
Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.
News from the year's biggest meetings
Clinical features with downloadable PDFs